Our Products

Our Products

The goal of Eventide Mutual Funds is to maintain market outperformance by investing in companies that we believe excel at creating value, operate with integrity, and profit from ethical and sustainable activities. We invite individuals, advisors, and institutions to learn more about our products below, including performance, holdings, prospectus, and other details.

Objective

Seeks to provide long-term capital appreciation

About the Fund

A diversified, equity mutual fund representing our “best ideas” that seeks to provide long-term capital appreciation. Historical emphases in small- and mid-cap growth, Health Care and Information Technology.

Investment Process

There is no guarantee that the Adviser’s Investment Process will produce the desired results. All investments involve risks, including possible loss of capital.

Dr. Finny Kuruvilla has a unique background in healthcare, statistics, and investing. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. He completed his residency and fellowship at the Brigham & Women’s Hospital and Children’s Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. As an avid proponent of values-based investing, Dr. Kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process.

David Barksdale has a background in software development, engineering and management and is primarily responsible for quantitative research, risk analysis and asset allocation. He holds a bachelor’s degree from Caltech in Engineering & Applied Science. By developing and applying novel analytical tools and strategies, Mr. Barksdale works to optimize portfolio returns on a risk-adjusted basis.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of September 30, 2017:

Eventide Gilead Fund Portfolio Composition

2. Companies valued at greater than $10 billion are Large Cap; those at less than $1 billion are Small Cap. Portfolio Composition is subject to change at any time, and should not be considered investment advice.

3. The Fund may not invest 25% or more of its total assets in a particular industry or group of industries. A sector is normally composed of many industry groups. Sector Allocation is subject to change at any time, and should not be considered investment advice.

As of September 30, 2017:

Fund Performance

Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information and a current Eventide Gilead Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).

Eventide Gilead Fund’s Class N expenses: Total Expenses 1.43%.

2. These charts compare the Eventide Gilead Fund Class N’s performance to index performance over the periods shown. Performance will differ for other fund classes, based upon fees and commissions. The Growth of $10,000 Chart assumes Class N’s inception date of 8 July 2008 for the indices.

3. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemption of Fund shares. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

4. The S&P 500 is an index created by Standard & Poor’s of American stocks with the largest market capitalization. It is not an investment product available for purchase. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The volatility of the indices may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the indices listed.

5. Performance figures for periods greater than 1 year are annualized. The Fund’s share classes have different inception dates. Class N has an inception date of 8 July 2008. Class A and Class C have an inception date of 28 October 2009. Class I has an inception date of 2 February 2010. The indices assume an inception date of 8 July 2008.

As of September 30, 2017:

EGF-market-risk

4. Source: © Morningstar, Inc. (2017). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Prior to June 30, 2017, this summary sheet sourced market risk data from Zephyr StyleADVISOR, including a 5-year measurement period. Other updates to this summary sheet include information intended to help investors assess performance and risk factors across near-term and longer-term periods (i.e., trailing 3-years and since inception) and risk data associated with the fund’s benchmarks. The performance and risk factor comparisons are against the S&P 500 Total Return Index (“Index”). Alpha is a measure of performance on a risk-adjusted basis. It takes the volatility (price risk) of a fund and compares its risk-adjusted performance to the Index. Any excess return of the fund relative to the return of the Index is a fund’s alpha. Beta is a measure of the volatility of a fund relative to the Index. A beta greater than 1 is more volatile than the Index. R-Squared measures how a fund’s performance correlates with the Index’s performance and it can help assess how likely it is that beta is statistically significant. Standard Deviation of return measures the amount of variation in historical performance from period to period.

5. Annualized since inception market risk details assume inception date of 1 August 2008 and not Class N’s actual inception date of 8 July 2008, as only full month data is included in the market risk calculations.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of September 30, 2017:

  • XPO Logistics Inc (4.14%) Global provider of transportation and logistics solutions
  • Macquarie Infrastructure Corp (3.51%) Aircraft services, liquid storage and marine terminals
  • Lowe’s Cos Inc (3.12%) 2,365 home improvement stores in the U.S., Canada, and Mexico
  • Bluebird Bio Inc (2.91%) Gene therapy, cancer immunotherapy, and gene editing
  • Lam Research Corp (2.90%) Supplying wafer fabrication equipment for the semiconductor industry
  • Wayfair Inc (2.63%) Online sales of furniture and home decor
  • AbbVie Inc (2.63%) Innovation-driven global biopharmaceuticals
  • WABCO Holdings Inc (2.61%) Technologies and services improving commercial vehicle safety, efficiency
  • SunOpta Inc (2.34%) Global organic food company
  • The Trade Desk Inc (2.31%) Digital advertising platform managing display, social, mobile, and video campaigns

Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

View the fact sheet, commentary, and presentation for the Eventide Gilead Fund.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

  • Equity mutual fund investing in healthcare and life sciences
  • Uses bottom-up fundamental research to find companies with the potential to appreciate in value as positive data is released regarding clinical trials and FDA feedback, and market acceptance of products.
  • Under normal market conditions, the Fund will invest at least 80 percent of its net assets in equity and equity-related securities of companies in the healthcare and life sciences sectors.

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. These companies include smaller development-stage companies.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Dr. Finny Kuruvilla has a unique background in healthcare, statistics, and investing. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. He completed his residency and fellowship at the Brigham & Women’s Hospital and Children’s Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. As an avid proponent of values-based investing, Dr. Kuruvilla has developed standards for selecting ethical companies at the outset of the stock selection process.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of September 30, 2017:

Portfolio Composition

2. Companies valued at greater than $10 billion are Large Cap; those at less than $1 billion are Small Cap. Portfolio Composition is subject to change at any time, and should not be considered investment advice.

3. Industry Allocation is subject to change at any time, and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of September 30, 2017:

EHLSF-performance

Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information and a current Eventide Healthcare & Life Sciences Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).

Eventide Healthcare & Life Sciences Fund’s Class N expenses: Net Expenses 1.55%.

2. These charts compare the Eventide Healthcare & Life Sciences Fund Class N’s performance to index performance over the periods shown. Performance will differ for other fund classes, based upon fees and commissions. The Growth of $10,000 Chart assumes the Fund’s inception date of 27 December 2012 for the indices.

3. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemption of Fund shares. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

4. The S&P 500 is an index created by Standard & Poor’s of American stocks with the largest market capitalization. It is not an investment product available for purchase. The Healthcare Blended Index is composed of equal parts of the S&P 400 Healthcare Index and the S&P 600 Healthcare Index from Fund inception on 27 December, 2012. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The secondary index for the Fund changed from the Healthcare Blended Index to the S&P Biotechnology Select Industry Index on April 1, 2017. This change was made because the Adviser believes that the composition of the S&P Biotechnology Select Industry Index better reflects the risks and opportunities of the Fund’s portfolio. The performance of both indices will be shown for a period of one year. Thereafter, the performance of the Healthcare Blended Index will no longer be shown on the Summary sheet. The volatility of the indices may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the indices listed.

5. Performance figures for periods greater than 1 year are annualized. Annualized since inception returns assume an inception date of 27 December 2012. Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information and a current Eventide Healthcare & Life Sciences Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of September 30, 2017:

Market Risk

4. Source: © Morningstar, Inc. (2017). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Prior to June 30, 2017, this summary sheet sourced market risk data from Zephyr StyleADVISOR. Other updates to this summary sheet include information intended to help investors assess performance and risk factors associated with the fund’s benchmarks. The performance and risk factor comparisons are against the S&P 500 Total Return Index (“Index”). Alpha is a measure of performance on a risk-adjusted basis. It takes the volatility (price risk) of a fund and compares its risk-adjusted performance to the Index. Any excess return of the fund relative to the return of the Index is a fund’s alpha. Beta is a measure of the volatility of a fund relative to the Index. A beta greater than 1 is more volatile than the Index. R-Squared measures how a fund’s performance correlates with the Index’s performance and it can help assess how likely it is that beta is statistically significant. Standard Deviation of return measures the amount of variation in historical performance from period to period.

5. Annualized since inception market risk details assume inception date of 1 January 2013 and not Fund’s actual inception date of 27 December 2012, as only full month data is included in the market risk calculations.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of September 30, 2017:

  • Blueprint Medicines Corp (3.88%) Developing a new generation of kinase therapies for genomically defined diseases
  • Bluebird Bio Inc (3.40%) Gene therapy, cancer immunotherapy and gene editing
  • Spark Therapeutics Inc (3.16%) Innovating gene therapies for inherited diseases
  • Ascendis Pharma A/S (2.87%) Rare-disease focused biopharmaceutical company
  • AKCEA THERAPEUTICS INC (2.74%) Targeted RNA medicines for cardiometabolic diseases
  • Voyager Therapeutics Inc (2.73%) Developing gene therapies for severe neurological diseases
  • Celgene Corp (2.59%) Discovery, development and commercialization of life-changing cancer therapies
  • Alnylam Pharmaceuticals Inc (2.49%) A pioneer in translating RNA Interference for medical applications
  • AbbVie Inc (2.31%) Innovation-driven global biopharmaceuticals
  • Loxo Oncology Inc (2.26%) Treating cancer at the genomic level with targeted chemical therapies

Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

View the fact sheet, commentary and presentation for the Eventide Healthcare & Life Sciences Fund.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Investment Objective: The Eventide Multi-Asset Income Fund seeks current income while maintaining the potential for capital appreciation. The Fund has significant flexibility to achieve its investment objective by primarily investing in a broad universe of income-producing securities. These securities include debt and equity securities of companies in the U.S. and other markets around the world.

These securities may include but are not limited to common stocks, real estate investment trusts (REITs), business development companies, yieldcos, master limited partnerships (MLPs), preferred stocks, corporate bonds, government agency bonds, certificates of deposit, municipal bonds, inflation-linked bonds, mortgage-backed securities, options, exchange traded notes, exchange traded funds and other investment companies (including mutual funds and closed-end funds). The Fund may invest up to 15% of its net assets in companies whose securities may have legal or contractual restrictions on resale or are otherwise illiquid.

Investment Strategy: Eventide uses a two step process to select securities for the Fund. The investment process begins with a “top down” analysis to select a variety of asset classes that are believed to offer the best opportunity for current income and/or capital appreciation. Factors considered include an assessment of current income opportunities, the potential for income growth, valuation, capital appreciation potential and/or portfolio risk/return attributes. The second step is a fundamental “bottom-up” analysis to evaluate specific securities for inclusion in the portfolio. Eventide favors securities that, in its opinion, are attractively valued, provide attractive current income, provide income appreciation potential, provide capital appreciation potential, and/or help to reduce overall portfolio volatility.

Sub-Adviser: Eventide has retained Boyd Watterson Asset Management, LLC to manage some or all of the Fund’s assets allocated for investment in the intermediate-term bond portion of the portfolio. In selecting securities for investment by the Fund, Boyd Watterson employs a top-down approach to determine how to structure the bond allocation taking in to consideration duration, maturity, and sector allocation. Boyd Watterson then initiates a process of security analysis based on several factors including, but not limited to, economic trends, industry assessments and issuer specific credit fundamentals.

Values-based investing: Eventide aims to analyze each potential investment’s ability to operate with integrity and create value for customers, employees, the environment, and other key stakeholders. While few companies may reach these ideals in every area of their business, these principles articulate the Advisor’s ideal characteristics of good corporate behavior. The Advisor makes no guarantee that fund investments will meet any or all of these characteristics.

Learn more about the Eventide Multi-Asset Income Fund in this presentation.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Martin Wildy, CFA serves on Eventide’s portfolio management team as the lead portfolio manager for the Eventide Multi- Asset Income Fund. Prior to joining Eventide in 2015, Mr. Wildy was a senior portfolio manager with Aris Wealth Services, a division of AssetMark, Inc. where he worked since 2006. Mr. Wildy served on Aris’s Investment Committee and was responsible for investment decisions that impacted a number of the firm’s investment strategies, including Aris’ Income Builder and values-based portfolios. In his role, Mr. Wildy’s responsibilities included developing capital market assumptions, asset allocation decisions, investment due diligence, and portfolio management. Mr. Wildy holds a bachelor’s degree from the Pennsylvania State University in Finance and has held the Chartered Financial Analyst (CFA) designation since 2003.

David M. Dirk, CFA serves as the Portfolio Manager for some or all of the fund’s intermediate-term bond portion. Mr. Dirk has been co-director of fixed Income for the fund’s sub-advisor, Boyd Watterson, with responsibility of directing all portfolio management and trading activity since 2011. This includes the implementation, execution, and evaluation of all strategies across Boyd Watterson’s suite of fixed income products. Mr. Dirk joined Duff & Phelps, predecessor to Boyd Watterson Asset Management, in 1996. David holds a CFA Charter from CFA Institute, an MBA from Case Western Resverve University, and a BA from Baldwin-Wallace College. He is also a member of the CFA Society of Cleveland and CFA Institute.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of September 30, 2017:

Portfolio Composition
5. Fund allocation percentages are subject to change at any time, and should not be considered investment advice. Included in the Cash/Other sections is a derivatives exposure of (0.0324%) % representing short call positions (covered calls) and short put positions (cash secured puts).

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of September 30, 2017:

Performance

Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information and a current Eventide Multi-Asset Income Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).

Eventide Multi-Asset Income Fund Class N expenses: Net Expenses 1.48%.

2. The numbers shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemption of Fund shares. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

3. The chart compares the Eventide Multi-Asset Income Fund Class N’s growth to index growth since inception, and assumes the Fund’s inception date of 15 July 2015 for the indices. Growth will differ for other fund classes, based upon fees and commissions.

4. The Multi-Asset Income Blend is a proprietary Eventide benchmark based on 60% MSCI All Country World Index (Net), 40% Barcap Aggregate Bond Index at inception, rebalanced monthly. The MSCI World All-Country World Index (Net) captures large and mid cap representation across 23 developed markets and 23 emerging markets. The volatility of the indices may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the indices listed.

5. The chart displays the Eventide Multi-Asset Income Fund Class N’s dividend and capital gains distributions for the periods shown. The distributions will differ for other fund classes, based upon fees and commissions. The total distribution may represent dividend and interest income, capital gains, and/or return of capital. Shareholders should not assume that the source of a distribution from the fund is net profit. The characterization of income is an estimate only and subject to change for tax purposes.

6. NAV presented is as of the date of the respective quarter end.

7. Source: Morningstar, Inc.

8. Performance figures for periods greater than 1 year are annualized. Annualized since inception returns assume an inception date of 15 July 2015.

As of September 30, 2017:

Market Risk

6. Source: © Morningstar, Inc. (2017). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Prior to June 30, 2017, this summary sheet sourced market risk data from Zephyr StyleADVISOR. Other updates to this summary sheet include information intended to help investors assess performance and risk factors associated with the fund’s benchmarks. The performance and risk factor comparisons are against the S&P 500 Total Return Index (“Index”). Alpha is a measure of performance on a risk-adjusted basis. It takes the volatility (price risk) of a fund and com- pares its risk-adjusted performance to the Index. Any excess return of the fund relative to the return of the Index is a fund’s alpha. Beta is a measure of the volatility of a fund relative to the Index. A beta greater than 1 is more volatile than the Index. R-Squared measures how a fund’s performance correlates with the Index’s performance and it can help assess how likely it is that beta is statistically significant. Standard Deviation of return measures the amount of variation in historical performance from period to period.

7. Since inception market risk details assume inception date of 1 August 2015 and not Class N’s actual inception date of 15 July 2015, as only full month data is included in the market risk calculations.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

As of September 30, 2017:

  • NextEra Energy Partners LP (2.51%) Yieldco for clean energy projects with stable, long-term cash flows
  • Spectra Energy Partners LP (2.43%) Energy infrastructure for transport and storage of natural gas
  • ABB Ltd (2.17%) Power systems, automation, and robotics for industrial applications
  • Macquarie Infrastructure Corp (2.13%) Aircraft services, bulk liquid storage and power production
  • Johnson Controls International plc (2.03%) HVAC, building controls, fire safety, battery solutions
  • Hannon Armstrong Sustainable Infrastructure (1.87%) Financing sustainable infrastructure projects
  • Brookfield Renewable Partners LP (1.83%) Global wind and hydroelectric power facilities
  • Schneider Electric SE (1.81%) Global specialist in energy management, efficiency and automation
  • First Hawaiian Inc (1.74%) Hawaii’s oldest and largest bank, offering diversified banking services
  • Atlantia SpA (1.73%) Owner and operator of global transportation infrastructure assets

Does not include Money Market Funds. Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

View the fact sheet, commentary and presentation for the Eventide Multi-Asset Income Fund.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

There is no guarantee that any investment will achieve its objectives, generate positive returns, or avoid losses. Past performance is not assurance of future results.

Mutual Funds involve risk including the possible loss of principal. Past performance does not guarantee future results.The funds’ ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards.

The Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Funds can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks. Investors in the Gilead Fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector also carry various risks including, but not limited to, risk related to debt loads and intense competition.

Investors in the Eventide Multi-Asset Income Fund should be aware that interest rates are at historic lows and may change at any time based on government policy. In general, the price of a fixed income security falls when interest rates rise. A rise in interest rates may result in volatility and increased redemptions, which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices. Longer-term securities may be more sensitive to changes in interest rates. The intermediate-term bond portion of the Multi-Asset Income Fund’s portfolio may represent 0% to 100% of the Fund’s portfolio with an average duration of between two and eight years. The Eventide Multi-Asset Income Fund may invest in other funds. If other funds are utilized, such underlying funds are subject to investment advisory and other expenses, which will be indirectly paid by the Fund. As a result, your cost of investing in the Fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds. The Fund may invest, directly or indirectly, in “junk bonds.” Such securities are speculative investments that carry greater risks than higher quality debt securities. There are unique risks associated with REITs, preferred stocks, convertible bonds, and BDCs that are covered in the Fund's prospectus and SAI.

The Eventide Multi-Asset Income Fund and Eventide Global Dividend Opportunities Fund can invest in MLPs and Yieldcos. MLPs carry unique risks including risks surrounding its tax status and risk pertaining to rising interest rates, both of which can negatively impact share price. Yieldcos carry different risks including Yieldco Sponsor Risk and cash flow risk. The Eventide Global Dividend Opportunities Fund is a new mutual fund and has a limited history of operations for investors to evaluate.

An investor should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA, which is not affiliated with Eventide Asset Management, LLC.

4309-NLD-4-25-2016